Surf Bio, a preclinical biopharmaceutical company focused on drug delivery innovation, has successfully raised $50.0 million in a recent funding round. This significant capital infusion is set to accelerate the company's mission to transform how antibodies and biologics are delivered to patients, further advancing its proprietary technology platform.
The core of Surf Bio's innovation is its Surf SnapShot™ technology. This platform is designed to enable ultra-high concentration formulations, allowing for mAb concentrations of up to 600 mg/mL. Crucially, it facilitates the delivery of a substantial dose, up to 1,000 mg, in a single, standard autoinjector shot. The SnapShot™ system's unique capabilities are powered by Surf Bio’s proprietary polymer, which aims to provide one of the most accessible and patient-friendly subcutaneous delivery methods for mAbs and biologics currently in development.
The $50.0 million in new funding represents a pivotal moment for Surf Bio, providing substantial resources to advance its strategic objectives. The company plans to deploy this capital to accelerate its preclinical programs, expand its research and development capabilities, and further optimize the Surf SnapShot™ platform. This investment underscores strong confidence in Surf Bio's potential to address critical unmet needs in drug delivery and improve patient adherence and convenience.
This funding round strategically positions Surf Bio for continued growth and innovation within the biopharmaceutical sector. The company is focused on leveraging this investment to progress its advanced delivery solutions through development, ultimately aiming to enhance treatment experiences and expand therapeutic options for a wide range of patients globally.
